Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.

Revumenib, venetoclax, and ASTX727 (a fixed-dose combination of decitabine and cedazuridine) demonstrated efficacy in patients with relapsed or refractory AML.

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic ...

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...